retatrutide phase 2 nejm 2023 weight loss percent 48 weeks 🚨 BREAKING: Shows “Bariatric-Level” in 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Eli Lilly's retatrutide shows promising

To put that into perspective, Ozempic and Wegovy are GLP-1 receptor agonists, while Zepbound and Mounjaro are dual GIP/GLP-1 receptor agonists

You may also see weight gain, which some people call "rebound weight gain." Clinical studies show that people often put back on some of the weight they lost after they stop taking the medicine

Drucker, a fellow in Habeners lab in the 1980s, outlined the processing of proglucagon and the biology of GLP-1 action on insulin-producing cells, which led to the development of multiple types of treatments for type 2 diabetes

Provider guidance built for women in midlife One-size-fits-all, not menopause-aware

Pieralice et al., 2025), demonstrating that therapeutic targeting of the metabolic axis is effective